objective response

You have access
Clinical Outcomes of the Optimized Weekly 8-Gy Palliative Radiotherapy Regimen
TAKESHI FUJISAWA, KENJI MAKITA, MASAKI NAKAMURA, HIDENARI HIRATA, HIDEHIRO HOJO, KEITA TSUKAHARA, HIDEKAZU OYOSHI, YUZHENG ZHOU and SADAMOTO ZENDA

Anticancer Research April 2026, 46 (4) 2133-2144; DOI: https://doi.org/10.21873/anticanres.18102
You have access
Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab–Durvalumab
AKIFUMI KUWANO, KOSUKE TANAKA, TAIKAN HAMAMOTO, KAZUKI KUROSAKA, HIDEO SUZUKI, MASAYOSHI YADA, YOSHIHIRO OHISHI, TOMONARI SASAKI and KENTA MOTOMURA

Anticancer Research December 2025, 45 (12) 5697-5708; DOI: https://doi.org/10.21873/anticanres.17903
You have access
Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
NAOTAKA SHIMOZATO, TADASHI NAMISAKI, AKIHIRO OKANO, MASAYA OHANA, DAISUKE KINOSHITA, TOSHIHIKO KAWASAKI, YOSUKE AIHARA, TOSHIYA NAKATANI, HIROKI KINOSHITA, TATSUICHI ANN, KO SAITO, MOTOYUKI YOSHIDA and HITOSHI YOSHIJI

Anticancer Research January 2022, 42 (1) 173-183; DOI: https://doi.org/10.21873/anticanres.15471
You have access
Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma
AYA TAKAHASHI, MICHIHISA MORIGUCHI, YUYA SEKO, HIROKI ISHIKAWA, TAKAHARU YO, HIROYUKI KIMURA, HIDEKI FUJII, TOSHIHIDE SHIMA, YASUHIDE MITSUMOTO, HIROSHI ISHIBA, HIDETAKA TAKASHIMA, YASUYUKI NAGAO, MASAYASU JO, MASAHIRO ARAI, TASUKU HARA, AKIRA OKAJIMA, AKIRA MURAMATSU, ATSUHIRO MORITA, NAOMI YOSHINAMI, TOMOKI NAKAJIMA, HIRONORI MITSUYOSHI, ATSUSHI UMEMURA, TAICHIRO NISHIKAWA, KANJI YAMAGUCHI and YOSHITO ITOH

Anticancer Research September 2019, 39 (9) 5149-5156; DOI: https://doi.org/10.21873/anticanres.13710
You have access
The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter
KENJI NAKAHAMA, SHUN-ICHI ISA, AKIHIRO TAMIYA, YOSHIHIKO TANIGUCHI, TAKAYUKI SHIROYAMA, HIDEKAZU SUZUKI, TAKAKO INOUE, MOTOHIRO TAMIYA, TOMONORI HIRASHIMA, FUMIO IMAMURA and SHINJI ATAGI

Anticancer Research October 2017, 37 (10) 5885-5891;
You have access
No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma
AKIRA MIYAZAKI, HIDEAKI MIYAKE, KEN-ICHI HARADA and MASATO FUJISAWA

Anticancer Research May 2015, 35 (5) 3067-3073;

Main menu

User menu

Search

objective response